> Dear allstaters,
>
> please find attached the latest contract vacancy for you to review;
>
> TITLE: Project Statistician - Phase II-III Oncology Trials
>
> ROLE: Essential, M.Sc/B.Sc/Phd in statistics, biostatistics or related
> subject, 3yrs+ minimum pharmaceutical/CRO experience, minimum 3yrs+
> statistics experience, SAS programming, SAS/base, SAS/macro & some phase
> II-III study experience. Desirable, dose justification analysis, logistic
> regression, exploratory analysis, submission project experience & any
> specific therapeutic knowledge in
> anti-fungal/anti-viral/anti-bacterial/anti-infectives. Working for this
> worldwide pharmaceutical giant on their worldwide phase II-III study, your
> duties will include; preparing/writing analysis plans for submission,
> implementing the statistical analysis plans, SAS programming (v6.12 on
> Unix), exploratory analysis & dose justification analysis. Accomodation is
> provided with this role and is not deducted from your rate. This is an
> exclusive role for a start when you are available, interview times await
> for an immediate decision.
>
> LOCATION: Germany
> CONTRACT LENGTH: 3 months+
> RATE: £ Excellent / hour - Dependant on experience
> START DATE: ASAP, but they will wait for notice periods
>
> If you interested in this role please feel free to contact me for further
> details at the earliest possible moment.
>
> Regards
>
> James Carrera
> European Contracts Manager
> Pharmaceutical, Healthcare & CRO division.
> 1st IT People
> Tel: +44 (0) 207 940 3900
> Fax: +44 (0) 207 886 8161
> mailto:[log in to unmask]
> www.1st-itpeople.com
>
> Offices in UK, Switzerland, The Netherlands & Hong Kong
> This email is confidential and intended solely for the use of the
> individual to whom it is addressed. Any views or opinions presented are
> solely those of the author and do not represent those of the company from
> which the email was sent. If you are not the intended recipient, be
> advised that you have received this e-mail in error and that any use,
> dissemination forwarding, printing or copying of this e-mail is strictly
> prohibited. While every effort has been made to scan this e-mail, we can
> not accept any responsibility for loss of business or damage caused
> arising from this e-mail.
>
This email is confidential and intended solely for the use of the
individual to whom it is addressed. Any views or opinions presented are
solely those of the author and do not represent those of the company from
which the email was sent. If you are not the intended recipient, be advised
that you have received this e-mail in error and that any use, dissemination
forwarding, printing or copying of this e-mail is strictly prohibited.
While every effort has been made to scan this e-mail, we can not accept any
responsibility for loss of business or damage caused arising from this
e-mail.
|